1. S256: TABELECLEUCEL FOR EBV-DRIVEN POST-TRANSPLANT LYMPHOPROLIFERATIVE DISEASE FOLLOWING ALLOGENEIC HEMATOPOIETIC CELL OR SOLID ORGAN TRANSPLANT AFTER FAILURE OF RITUXIMAB ± CHEMOTHERAPY (ALLELE). (23rd June 2022) Authors: Prockop, S.; Beitinjaneh, A.; Choquet, S.; Dahiya, S.; Dinavahi, R.; Farah, R.; Gamelin, L.; Ghobadi, A.; Mehta, A.; Nayak, P.; Reshef, R.; Satyanarayana, G.; Stiff, P.; Ye, W.; Mahadeo, K. M. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 157 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗